Mankind Pharma Limited
Momentum (76/100) does the heavy lifting; valuation (18/100) is the drag.
Fair valueOvervaluedOur blended model reads Mankind Pharma Limited as a Hold at 45/100. At ₹2,469.6 it trades above our blended DCF and relative-multiples fair value of ₹1,564.42, about 37% downside to that estimate — we read it as overvalued by 37%. On 53.7x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 7% below its 52-week high of ₹2,660.6 and 28% above the low of ₹1,927.4. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹2,656.4 implies about 8% upside across 20 analysts. It clears 8 of 13 investability checks, with durability 60, valuation 36 and momentum 76 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,251.54.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-7.18% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 12.5%
- Pass: Low debt (D/E < 0.5): 0.38x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Pass: Earnings growing: 32%
- Pass: Net margin ≥ 10%: 13.4%
- Fail: Current ratio > 1.5: 1.07
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.46
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter75.4%
- Institutions20.1%
- Public & other4.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 6.46.
Opportunities
- Earnings growing (32% YoY).
Bear case
Threats
- Trades ~37% above our estimated fair value.
About Mankind Pharma Limited
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across India and international markets. Its pharmaceutical portfolio addresses acute and chronic conditions including anti-infective, cardiovascular, gastrointestinal, gynaecological, anti-diabetic, dermatological, pain management, neurological, respiratory, and nutritional therapies. The company also produces consumer healthcare products.
Mankind Pharma Limited — frequently asked questions
Is Mankind Pharma Limited a buy, hold or sell?
StocksWizard currently rates Mankind Pharma Limited (MANKIND) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Mankind Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Mankind Pharma Limited's fair value at about ₹1,564.42, versus a current price of ₹2,469.6 — roughly 37% downside. On that basis the stock looks overvalued by 37%.
Is Mankind Pharma Limited financially healthy?
Mankind Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Mankind Pharma Limited's share price performed?
Mankind Pharma Limited is up 6% over three months, and last traded at ₹2,469.6. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.